Current Report Filing (8-k)
June 12 2019 - 1:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 12, 2019
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-32335
|
|
88-0488686
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
11388 Sorrento Valley Road, San Diego, California
|
|
92121
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (858)
794-8889
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value
|
|
HALO
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities
Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On June 12, 2019, Halozyme Therapeutics, Inc., a Delaware corporation (Halozyme), announced that it had reached the target
number of 330 overall survival events in its
HALO-301
clinical trial and that it plans to conduct the final overall survival analysis upon data maturity which will occur when all patients enrolled in the
study have been followed for at least 8.5 months. Accordingly, Halozyme projects to achieve data maturity in
mid-September
2019. Based on this timing of data maturity, Halozyme expects to announce top line
results for the
HALO-301
clinical trial by December 2019.
Cautionary Statement Regarding Forward-Looking
Statements
In addition to historical information, the statements set forth above in this Item 8.01 include forward-looking
statements (including, without limitation, statements concerning the expected timing of receipt of data maturity for clinical trial
HALO-301
and the announcement of top line results for
HALO-301)
that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always,
identified through use of the words believe, enable, may, will, could, intends, estimate, anticipate, plan, predict,
probable, potential, possible, should, continue, and other words of similar meaning. Actual results could differ materially from the expectations contained in these forward-looking
statements as a result of several factors, including unexpected delays in the conduct of the
HALO-301
study or the analysis of
HALO-301
data, unexpected regulatory
requirements or unexpected adverse events. These and other factors that may result in differences between the forward-looking statements and actual results are discussed in greater detail in the Halozymes annual and quarterly reports filed
with the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Halozyme Therapeutics, Inc.
|
|
|
|
|
June 12, 2019
|
|
|
|
By:
|
|
/s/ Harry J. Leonhardt
|
|
|
|
|
|
|
Harry J. Leonhardt, Esq.
|
|
|
|
|
|
|
Senior Vice President, General Counsel
and
Corporate Secretary
|
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Sep 2023 to Sep 2024